DCPH - デシフィラ・ファ―マシュ―ティカルズ （Deciphera Pharmaceuticals Inc.） デシフィラ・ファ―マシュ―ティカルズDCPHのチャート
DCPHの企業情報
| symbol | DCPH |
|---|---|
| 会社名 | Deciphera Pharmaceuticals Inc （デシフィラ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 デシフェラ・ファーマシューティカルズ(Deciphera Pharmaceuticals Inc.)は臨床段階の製薬会社である。同社はがん患者の生活を改善するための薬物を開発している。同社の薬剤候補には、DCC-2618、DCC-3014およびレバスチニブが含まれる。独自のキナーゼスイッチ制御阻害剤プラットフォームは、キナーゼの活性化を阻害する。DCC-2618はDCC-2618は、消化管間質腫瘍（GIST）、進行性全身性肥満細胞症（ASM）、神経膠芽細胞腫（GBM）およびpan-KITまたはPDGFRアルファによって駆動される他の固形腫瘍の治療用経口投与キナーゼスイッチ制御阻害剤である。DCC-3014は、コロニー刺激因子受容体1（CSF1R）の経口投与された強力かつ高度に選択的な阻害剤である。レバスチニブは、経口的に投与され、TIE2免疫キナーゼの強力で選択的な阻害剤である。レバスチニブは、TIE2のスイッチポケットに強力に結合し、阻害スイッチを安定化させ、活性化スイッチを変位させてTIE2シグナル伝達を遮断する。 デシフィラ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がん治療の反応速度を制限する薬剤耐性のメカニズムを研究し、がん患者の生活を改善する新薬の開発に従事する。同社独自のキナ―ゼスイッチ制御阻害プラットフォ―ムによる小分子薬物候補は、多くのがんが転移することを防ぐために開発される。本社所在地はマサチュ―セッツ州ウォルサム。 deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers. |
| 本社所在地 | 500 Totten Pond Road Waltham MA 02451 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 781-209-6400 |
| 設立年月日 | 42948 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | － |
| url | www.deciphera.com |
| nasdaq_url | https://www.nasdaq.com/symbol/dcph |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -76.68100 |
| 終値（lastsale） | 30.84 |
| 時価総額（marketcap） | 1161348078.84 |
| 時価総額 | 時価総額（百万ドル） 1182.06 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 836.92100 |
| 当期純利益 | 当期純利益（百万ドル） -75.07000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Deciphera Pharmaceuticals Inc revenues was not reported. Net loss increased from $18.3M to $43.1M. Higher net loss reflects Research and development increase from $13.8M to $33M (expense) General and administrative increase of 97% to $7.2M (expense) Share-based compensation in Selling Gen increase from $672K to $2.3M (expense). |
DCPHのテクニカル分析
DCPHのニュース
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK at the 2023 American Society of Clinical Oncology Annual Meeting 2023/05/25 21:00:00 Wallstreet:Online
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced four poster presentations at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on June 2-6, 2023. “As we prepare to
State Board of Administration of Florida Retirement System Sells 5,080 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) 2023/05/22 09:09:52 EIN News Pharmaceuticals
… decreased its position in Deciphera Pharmaceuticals , Inc. (NASDAQ:DCPH – Get … for the current year. Deciphera Pharmaceuticals Company Profile (Get Rating) Deciphera … analysts'' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat …
State Board of Administration of Florida Retirement System Cuts Stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) 2023/05/22 08:58:41 The AM Reporter
State Board of Administration of Florida Retirement System lessened its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) by 23.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,620 shares of the company’s stock after selling 5,080 shares during […]
NEW THERAPY FOR RARE GASTROINTESTINAL STROMAL TUMOURS APPROVED IN SINGAPORE 2023/05/07 20:00:00 Kwhen Finance
Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2023 Earnings Call Transcript 2023/05/07 08:58:09 Seeking Alpha
Deciphera Pharmaceuticals, Inc. (NASDAQ:NASDAQ:DCPH) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ETCompany ParticipantsJen Larson - Senior Vice President-Finance and Investor…
NEW THERAPY FOR RARE GASTROINTESTINAL STROMAL TUMOURS APPROVED IN SINGAPORE 2023/05/07 20:00:00 Kwhen Finance
Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2023 Earnings Call Transcript 2023/05/07 08:58:09 Seeking Alpha
Deciphera Pharmaceuticals, Inc. (NASDAQ:NASDAQ:DCPH) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ETCompany ParticipantsJen Larson - Senior Vice President-Finance and Investor…
Stifel maintains Deciphera Pharma at Hold with a price target of $14.00 2023/05/04 19:11:37 Investing.com
https://www.investing.com/news/pro/deciphera-pharmaceuticals-receives-investment-bank-analyst-rating-update-3073306
Deciphera Pharmaceuticals GAAP EPS of -$0.60 misses by $0.01, revenue of $33.45M misses by $2.05M 2023/05/03 11:25:22 Seeking Alpha
Deciphera Pharmaceuticals press release (NASDAQ:DCPH): Q1 GAAP EPS of -$0.60 misses by $0.01.Revenue of $33.45M (+14.6% Y/Y) misses by $2.05M.
Recap: Deciphera Pharmaceuticals Q1 Earnings 2023/05/03 11:20:16 Benzinga
Deciphera Pharmaceuticals (NASDAQ: DCPH ) reported its Q1 earnings results on Wednesday, May 3, 2023 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Deciphera Pharmaceuticals missed estimated earnings by 1.69%, reporting an … Full story available on Benzinga.com
Deciphera Pharmaceuticals, Inc.(DCPH) Investor Presentation - Slideshow 2023/03/29 15:49:16 Seeking Alpha
The following slide deck was published by Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals: In The Middle Of A Major Comeback (Upgrade) 2023/03/25 12:00:00 Seeking Alpha
Last year, Deciphera Pharmaceuticals was almost destroyed by a trial failure. This year, it has had some good omens. Click here for our analysis of DCPH stock.
Deciphera Pharmaceuticals: INTRIGUE Phase 3 Shows Substantial Benefit 2023/03/18 09:21:53 Seeking Alpha
Deciphera reported total revenue of $36.3M for Q4 2022, an increase from $24.2M YoY. Learn why investors should consider DCPH as a promising long-term investment opportunity.